SuFEx Click Chemistry Enabled Late-Stage Drug Functionalization.

SuFEx Click Chemistry Enabled Late-Stage Drug Functionalization.
复制标题

Sufex点击化学启用后期药物功能化。

DOI:
10.1021/jacs.7b12788
复制
发表时间:
2018-02-28
影响因子:
15
通讯作者:
Wu P
Wu P
中科院分区:
化学1区
文献类型:
--
作者:
Liu Z;Li J;Li S;Li G;Sharpless KB;Wu P

文献摘要

参考文献

被引文献

相似文献

硫 (VI) 氟化物交换 (SuFEx) 是点击化学转化的一个新家族,它依赖于现成的材料来生产带有 SVI-F 基序的化合物。 SuFEx 在药物发现方面的潜力才刚刚开始被探索。我们报告了第一种 SuFEx 化学方法,用于在 96 孔板中将酚类化合物原位转化为其各自的芳基氟硫酸盐衍生物。该方法与自动合成和筛选兼容,可快速评估原位生成的粗产物的生物活性。使用这种方法,我们对一组已知的抗癌药物进行后期功能化,以生成相应的芳基氟硫酸盐。这些原位生成的芳基氟硫酸盐与其酚类前体同时在癌细胞生长抑制测定中直接进行测试。我们发现三种芳基氟硫酸盐与其苯酚前体相比表现出更好的抗癌细胞增殖活性。在这三种化合物中,氟维司群的氟硫酸盐衍生物在ER+乳腺癌细胞系M CF-7中具有显着增强的下调雌激素受体(ER)表达的活性,而Combretastatin A 4的氟硫酸盐衍生物(目前正在临床试验中评估的通用抗癌药物)在耐药性结肠癌细胞系HT-29中的效力增加了70倍。
Sulfur(VI) Fluoride Exchange (SuFEx) is a new family of click chemistry transformations which relies on readily available materials to produce compounds bearing the SVI—F motif. The potential of SuFEx in drug discovery has just started to be explored. We report the first method of SuFEx chemistry for the conversion of phenolic compounds to their respective arylfluorosulfate derivatives in situ in 96-well plates. This method is compatible with automated synthesis and screening to quickly assess the biological activities of the in situ generated, crude products. U sing this method, we perform late-stage functionalization of a panel of known anticancer drugs to generate the corresponding arylfluorosulfates. These in situ generated arylfluorosulfates are directly tested in a cancer-cell growth inhibition assay in parallel with their phenolic precursors. We discover three arylfluorosulfates that exhibit improved anticancer cell proliferation activities compared to their phenol precursors. Among these three compounds, the fluorosulfate derivative of Fulvestrant possesses significantly enhanced activity to down-regulate estrogen receptor (ER) expression in ER+ breast cancer cell line M CF-7 and the fluorosulfate derivative of Combretastatin A 4—a general anticancer drug currently being evaluated under clinical trials—exhibits a 70-fold increase in potency in the drug resistant colon cancer cell line HT-29.
DOI: 10.1002/anie.201611048
发表时间: 2017-03-06
期刊: Angewandte Chemie (International ed. in English)
影响因子: --
作者:
Li S;Wu P;Moses JE;Sharpless KB
通讯作者: Sharpless KB
DOI: 10.3390/molecules18089797
发表时间: 2013-08-16
期刊: Molecules (Basel, Switzerland)
影响因子: --
作者:
Li H;Aneja R;Chaiken I
通讯作者: Chaiken I
DOI: 10.1126/science.aam7355
发表时间: 2017-06-09
期刊: Science (New York, N.Y.)
影响因子: --
作者:
Li C;Wang J;Barton LM;Yu S;Tian M;Peters DS;Kumar M;Yu AW;Johnson KA;Chatterjee AK;Yan M;Baran PS
通讯作者: Baran PS
DOI: 10.1002/anie.201403758
发表时间: 2014-09-01
影响因子: 16.6
作者:
Dong, Jiajia;Sharpless, K. Barry;Kwisnek, Luke;Oakdale, James S.;Fokin, Valery V.
通讯作者: Fokin, Valery V.
DOI: 10.1021/acschembio.7b00403
发表时间: 2017-08-01
影响因子: 4
作者:
Fadeyi, Olugbeminiyi O.;Hoth, Lise R.;Jones, Lyn H.
通讯作者: Jones, Lyn H.